Evolution of Chronic Kidney Disease: Defining a Model for Care

World Congress of Nephrology (ASN/ISN), San Francisco, CA, October, 2001

A Welcome and Introductory Remarks

Paul Kimmel, M.D.
Professor of Medicine
Director, Division of Nephrology
George Washington University
Medical Center
Washington, DC, USA

Ajay Singh, M.B., M.R.C.P.
Associate Professor of Medicine, Harvard School of Medicine, Clinical Director / Renal Division, Director of Dialysis, Brigham and Women's Hospital, Boston, MA, USA

Please make sure that all slide images load before starting the lecture

Windows Media Player
Option 1Streaming Server
Option 2For slow connections, right click on preload icon and choose "save target as". Play file from saved location.

Real Audio Player
Option 3 Streaming, Firewall-friendly
Option 4 Preload (2-5 mB)

Audio FAQ
For problems and suggestions, please click on this link.



Post-test and evaluation form are at this link, but you must listen to all talks from this symposium prior to completing the test.
CME: The University of Minnesota is accredited by the Accreditation Council for Continuing Medical Education (AACME) to sponsor continuing medical education for physicians.
The University of Minnesota designates this educational activity for up to 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity.

CEU: These talks are also designated to provide 1.5 hours of CEU Nursing Education credits, sponsored by the Renal Education Association. The Renal Education Association is accredited by the State of California Board of Nursing to provide continuing education for nurses (Provider number: CEP 13092).

Posting date: January 15, 2002.
Review date: January 15, 2003
After participating in this activity, participants should be able to:
Discuss the prevalence of chronic kidney disease (CKD) in the US population and suboptimal treatment of anemia;
Summarize the advances made in defining the stages of CKD and describe current guidelines for anemia correction;
Describe the effects of the correction of anemia on cardiorenal function in patients with congestive heart failure (CHF): and
Summarize knowledge about treatment plans and models of care that are directed at improving CKD treatment and limiting progression of disease.

Singh, Ajay: Consultant to: Ortho Biotech, Amgen, Pfizer, Merck, Pharmacia, Genzyme; Research Support: Amgen, Ortho Biotech. Kimmel, Paul: No potential conflicts of interest.

The CME policy statements of The University of Minnesota which is the accrediting organization for this talk, are given in detail on the Symposium Home Page. CME policy and disclosure statements of HDCN are listed on this page.


Moderator (Paul Kimmel, MD):
I'd like to welcome you. Please continue your dinner. My name is Paul Kimmel from George Washington University. I am here to welcome you to this World Congress of Nephrology official symposium today on "The Evolution of Chronic Kidney Disease: Defining a Model For Care."

This is a special symposium because it is a joint effort of the American Society of Nephrology and Ortho Biotech Products, L.P. We're very excited about this program. As I can see by your attendance, you are as well. I think we'll try to have a very quick set of presentations, 20 minutes a speaker, and we'll have a half hour for questions at the end of the presentation.

Now I would like to introduce Dr. Ajay Singh, who is the Clinical Director of the renal division and the Director of Dialysis at the Brigham and Women's Hospital in Boston, Massachusetts, and Associate Professor of Medicine at Harvard Medical School.

Ajay K. Singh, MD:
Thanks Paul. I would like to also welcome you. This is a very important area nowadays. It's an area that we all read about and certainly practice in our offices. What we're going to do is have a very exciting program for you.


The Ten A's of CKD
When we look into management of chronic kidney disease in 2001, I think we would all agree that it's a multidisciplinary effort with a long list of problems that we often have to grapple with. Each one of you has your own mental list of problems that you click off as you see patients in the office. This is my own list. The purpose of showing you this slide is just to show you that there are so many issues that we deal with when we see patients with chronic kidney disease.

Today, what we're going to do is probably focus most of our attention on anemia because it's certainly a very important area. It's a very important topical area, as well as being something that's treatable. But I just want to emphasize to you that this does not mean that we don't consider any of these other areas important. This meeting of the World Congress of Nephrology has addressed many of these issues.


The objectives of this evening's program are threefold: prevalence and current treatment of chronic kidney disease, optimizing anemia management in patients with chronic kidney disease, and then this very vexing issue about correcting mild anemia in severe resistant CHF and showing how this has an important impact on cardiorenal function. To introduce the first speaker, Dr. Kimmel is going to come back to the microphone.


This educational activity is supported by an educational grant from Ortho Biotech Products, L.P.
This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.
This educational activity is based on an ASN/ISN evening symposium which was
planned by the World Congress of Nephrology program committee.